Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The effect of knockdown of amphiregulin or SGK3 on global gene expression in letrozole resistant breast cancer cells

ABSTRACT: The effect of knockdown of amphiregulin or SGK3 on global gene expression in letrozole resistant breast cancer cells

PROVIDER: PRJNA625749 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11557547.fastq.gz	Fastqsanger.gz
	SRR11557548.fastq.gz	Fastqsanger.gz
	SRR11557549.fastq.gz	Fastqsanger.gz
	SRR11557550.fastq.gz	Fastqsanger.gz
	SRR11557551.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 9

Similar Datasets

The effect of knockdown of amphiregulin or SGK3 on global gene expression in letrozole resistant breast cancer cells

Project description:LET-R cells were reversely transfected with siRNA negative control, AREG siRNA or SGK3 siRNA for 48 h, and then harvested for RNA sequencing.

2020-04-23 | GSE148800 | GEO

Characterization of SGK3-PROTAC1, a highly specific SGK3 kinase PROTAC degrader

Project description:SGK3 is a PX domain containing protein kinase activated at endosomes downstream of Class 1 and 3 PI3K family members by growth factors and oncogenic mutations. SGK3 plays a key role in mediating resistance of breast cancer to Class 1 PI3K or Akt inhibitors, by substituting for loss of Akt and restoring proliferative pathways such as mTORC1 signaling. Here we describe the development of SGK3-PROTAC1, a Proteolysis Targeting Chimera (PROTAC) compound formed by the fusion of the 308-R SGK3 inhibitor with the VH032 VHL binding ligand via a 13-atom linker. In HEK293 cells, 0.3 µM SGK3-PROTAC1 induced 50% degradation of endogenous SGK3 within 2 hours, with maximal 85% degradation observed within 8 hours, accompanied by a loss of phosphorylation of NDRG1, an SGK3 substrate. SGK3-PROTAC1 did not degrade closely related SGK1 and SGK2 isoforms and proteomic analysis in HEK293 cells revealed that SGK3 was the only cellular protein whose cellular levels was significantly reduced following treatment with SGK3-PROTAC1. Low doses of SGK3-PROTAC1 (0.1-0.3 µM) restored sensitivity of SGK3 dependent ZR-75-1 and CAMA-1 breast cancer cells to Akt (AZD5363) and PI3K (GDC0941) inhibitors, under conditions which an epimer analogue incapable of binding to the VHL E3 ligase had no impact. SGK3-PROTAC1 suppressed proliferation of ZR-75-1 and CAMA-1 cancer cell lines treated with a PI3K inhibitor (GDC0941) more effectively than could be achieved by a conventional SGK isoform inhibitor (14H). This work provides a further example of the benefit of the PROTAC approach in targeting protein kinase signaling pathways with greater efficacy and selectivity than can be achieved with conventional inhibitors. SGK3-PROTAC1 will be an important reagent to explore the roles of the SGK3 pathway.

2019-11-12 | PXD013779 | Pride

SGK3 Orchestrates Glucocorticoid Signaling to Facilitate Chromatin Remodeling During Adipogenesis

Project description:Excessive glucocorticoid exposure is associated with significant metabolic side effects, partly attributed to the transcriptional regulation of adipogenesis by the Glucocorticoid receptor (GR). However, emerging evidence suggests the involvement of alternative pathways beyond GR activation, which are inadequately explored. Through quantitative phosphoproteomics analysis, we identified a significant enrichment of rapidly phosphorylated proteins harboring the RxxS motif following glucocorticoid exposure. Notably, a subset of these proteins undergoes phosphorylation at the RxxS motif by Serum- and glucocorticoid-induced kinase 3 (SGK3) upon glucocorticoid stimulation in preadipocytes. SGK3 emerges as a critical mediator of glucocorticoid-induced preadipocyte differentiation, supported by genetic ablation and pharmacological inhibition experiments that demonstrate impaired adipogenesis both in vitro and in vivo. Mechanistically, upon glucocorticoid stimulation, SGK3 translocates to the nucleus and directly interacts with the core ATPase subunit of the BAF chromatin remodeling complex, BRG1, leading to phosphorylation at threonine 428 and serine 1417 residues. This phosphorylation event prevents proteasomal degradation of BRG1, facilitating chromatin remodeling essential for adipogenesis. Furthermore, Sgk3 knockout mice exhibit resistance to obesity induced by either glucocorticoids or a high-fat diet (HFD). These findings illuminate novel roles of glucocorticoids beyond GR-mediated transcriptional control, highlighting SGK3 as a promising therapeutic target for mitigating metabolic side effects associated with glucocorticoid therapy.

2025-07-15 | GSE268382 | GEO

Small RNA-seq of breast tumor biopsies prior to treatment with letrozole or letrozole with bevacizumab

Project description:Biopsies were collected from post-menopausal women with ER+ HER2- breast cancer who were subsequently treated with either letrozole or letrozole plus bevacizumab.

2019-12-19 | GSE142308 | GEO

In vitro reconstitution of Sgk3 activation by phosphatidylinositol-3-phosphate

Project description:Serum- and glucocorticoid-regulated kinase 3 (Sgk3) is activated by the phospholipid 19 phosphatidylinositol-3-phosphate (PI3P) downstream of growth factor signaling and 20 by Vps34-mediated PI3P production during autophagy. Upregulation of Sgk3 activity 21 has been linked to a number of human cancers due to its overlapping substrate 22 specificity with Akt. Here, we show that Sgk3 is regulated by a combination of 23 phosphorylation and allosteric activation by PI3P. We demonstrate that Sgk3 is 24 specifically activated by PI3P and that PI3P binding induces large conformational 25 changes in Sgk3. Using Vps34 and liposomes containing phosphatidylinositol, we 26 reconstitute Sgk3 signaling via Vps34-mediated PI3P synthesis in vitro. In addition to 27 defining the mechanism of Sgk3 activation by PI3P, our findings open up potential 28 therapeutic avenues in allosteric inhibitor development to target Sgk3 in cancer.

2021-09-22 | PXD025327 | Pride

ER ChIP-seq of Androstenedione treated Letrozole Resistant Breast Cancer Cell line

Project description:Acquired resistance to aromatase inhibitor (AI) therapy is a major clinical problem in the treatment of breast cancer. The detailed mechanisms of how tumour cells develop this resistance remain unclear. Here estrogen receptor ChIPseq analysis identifies adaptations of the ER in response to prolonged letrozole treatment.

2016-03-21 | GSE54592 | GEO

Identification of Syntaxin 7 and 12 as the first selective substrates for SGK3

Project description:Deregulation of the PI3K/Akt pathway is a common feature in many types of cancer. Recent data has demonstrated that prolonged inhibition of breast cancer cell lines with PI3K and Akt inhibitors leads to up-regulation and increased activity of the AGC kinase Serum and glucocorticoid activated kinase 3, SGK3, which in turn substitutes for Akt and leads to activation of mTORC1. SGK3 and Akt exhibit similar substrate specificity for Ser/Thr residues in the RxRxxS/T motif. However, SGK3 can be regulated by both PI3K class I and class III and possesses a unique PX domain, enabling it to bind to PI(3)P lipids in endosomes. Still, the known SGK3 substrates are either shared or have not been tested whether Akt can phosphorylate them. In the present study, we undertook genetic and pharmacologic phosphoproteomic screens to search for selective SGK3 substrates. We identified a significant number of potential in vivo SGK3 selective substrates, including the endosomal proteins STX7, STX12, RFIP4 and WDR44. In vitro phosphorylation studies demonstrated that these substrates were directly phosphorylated at the sites identified in vivo by SGK3 but, unlike all other SGK3 substrates reported, not by Akt. We provide evidence that endogenous STX7 and STX12 are physiological SGK3 substrates whose phosphorylation is potently stimulated by IGF1. Our data pinpoint that STX7 and STX12 are the first selective SGK3 substrates in vivo and this phosphorylation enhances their interaction with the respective SNARE complexes. Finally, we suggest that STX7 and STX12 phosphorylation can be utilised as in vivo biomarkers for SGK3 activity.

2020-05-26 | PXD014561 | Pride

White adipose tissues: amphiregulin overexpression

Project description:Transcriptional profiling of transgenic mice specifically expressing amphiregulin in white adipose tissues. The objective of this study is to explore gene expression profiles of adipose tissues in response to amphiregulin overexpression.

2017-09-15 | GSE103875 | GEO

RNA sequencing of ER+ breast tumor treated with letrozole

Project description:Transcriptome of ER+ breast tumors treated with letrozole were profiled by RNA-seq

2020-07-01 | GSE145325 | GEO

Expression data from MCF7 tumor xenografts treated with either single agent BMS754807, or Tamoxifen or Letrozole alone; or Tamoxifen or Letrozole in combination with BMS754807 for 28 days

Project description:breast cancer. Combined IGF and estrogen-targeted therapy may improve the benefit of hormonal therapy alone. We employed a postmenopausal model of estrogen-dependent breast cancer in vitro and in vivo using the aromatase-expressing MCF-7/AC-1cells. Using this model, we investigated the anti-tumor effects of the dual IGF-1R/InsR tyrosine kinase inhibitor, BMS-754807 alone and in combination with letrozole or tamoxifen in vivo. We used microarrays to compare gene expression changes of MCF7 breast xenograft treated with either BMS754807, or Tamoxifen or Letrozole alone; or Tamoxifen or Letrozole in combination with BMS754807 for 28 days Breast xenograft MCF7 bearing mice treated with either BMS754807, or Tamoxifen or Letrozole alone; or Tamoxifen or Letrozole in combination with BMS754807 for 28 days. RNA were extracted from tumors and hybridizedon Affymetrix microarrays to compare gene expression changes

2011-11-02 | E-GEOD-33366 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data